Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Calderon-Alicea

Hematology & Oncology Toa Baja, PR Medical Doctor

NPI 1285883520 CMS profile 656829

Jr1 Calle Lizzie Graham, Levittown, Toa Baja, PR 00949

Open in the dashboard

General payments

$13,988

575 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Calderon-Alicea of Toa Baja, PR is reported in the CMS Open Payments database as having received $13,988 across 575 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,043 77
2024 General $2,191 75
2023 General $1,969 77
2022 General $1,713 75
2021 General $1,753 77
2020 General $2,043 95
2019 General $2,276 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Calderon-Alicea
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Elizabeth Calderon-Alicea were reported at $2,043. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Elizabeth Calderon-Alicea Hematology & Oncology median Middle half National median
2019 $2,276 $529 $121–$2,516 $163
2020 $2,043 $339 $82–$2,213 $114
2021 $1,753 $263 $49–$1,965 $132
2022 $1,713 $416 $103–$2,395 $149
2023 $1,969 $542 $125–$2,646 $160
2024 $2,191 $692 $141–$3,008 $164
2025 $2,043 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,819 81 payments
  2. E.R. Squibb & Sons, L.L.C. $1,335 65 payments
  3. Janssen Pharmaceuticals, Inc $1,167 52 payments
  4. Genentech USA, Inc. $919 45 payments
  5. PBG Puerto Rico LLC $904 42 payments
  6. Merck Sharp & Dohme Corporation $895 43 payments
  7. AbbVie, Inc. $814 31 payments
  8. Genzyme Corporation $791 22 payments
  9. Amgen Inc. $753 24 payments
  10. Eli Lilly Export S.A. Puerto Rico Branch $743 33 payments
  11. Other $3,849 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,947 556 payments
  2. Education $1,041 19 payments
Products named General payments · program years 2019–2025
  1. OPDIVO $974 47 payments
  2. KEYTRUDA $831 40 payments
  3. ERLEADA $819 25 payments
  4. SARCLISA $712 18 payments
  5. VERZENIO $696 31 payments
  6. XGEVA $480 19 payments
  7. TECENTRIQ $464 25 payments
  8. CYRAMZA $437 22 payments
  9. TAGRISSO $431 21 payments
  10. XTANDI $421 16 payments
  11. Other $12,422 547 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

590

Median for Hematology-Oncology: 604

Drug cost

$1,529,643

Median for Hematology-Oncology: $1,306,514

Branded share of claims

25.6%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Verzenio Abemaciclib Brand 33 $508,621
Erleada Apalutamide Brand 45 $397,613
Sprycel Dasatinib Brand 22 $225,190
Tagrisso Osimertinib Mesylate Brand 13 $222,462
Lenalidomide Generic 11 $160,238
Retacrit Epoetin Alfa-Epbx Brand 16 $6,789
Fentanyl Generic 15 $2,157
Hydroxyurea Generic 24 $1,168
Raloxifene Hcl Generic 13 $1,161
Anastrozole Generic 31 $1,103

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$3,077

Medicare's payments for the services billed

Medicare patients

16

Average age 74

Services billed

79

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 55 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $200
  • Janssen Pharmaceuticals, Inc $69
$269 45 —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $168
$168 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $133
$133 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $125
$125 — —
ELAHERE
  • AbbVie, Inc. $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 55 with Patron

Records

575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record